Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 7/20 | 0.66 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.61 |
| ▸ | PI4KA | P42356 | 3/20 | 0.57 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.57 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.57 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12157236 | 1.00 | AHCY (0.66) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL12173989 | 1.00 | AHCY (0.66) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL9308490 | 0.93 | AHCY (0.70) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL12858753 | 0.90 | ADORA2A (0.64) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL4894825 | 0.90 | ADORA2A (0.64) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL9686973 | 0.89 | ADORA2A (0.58) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10521577 | 0.86 | AHCY (0.61) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL10395085 | 0.86 | AHCY (0.48) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL9309056 | 0.86 | ADORA2A (0.69) | AHCYADORA2BADORA2AADORA3ADORA1 | |
| SCHEMBL9308668 | 0.86 | ADORA2A (0.69) | AHCYADORA2BADORA2AADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I. (CZ) | 2023-09-26 | — | — | US | disclosed |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY ASCR, V.V.I (CZ) | 2022-05-26 | — | — | US | disclosed |
| US-5155112-A | Antiviral agents; Herpes virus | GLAXO GROUP LIMITED (GB) | 1992-10-13 | — | — | US | disclosed |
| EP-0430518-A2 | Cyclopentane derivatives | GLAXO GROUP LIMITED (GB) | 1991-06-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766447-B2 | 3′3′-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator | STING1, MAVS, CGAS | AHCY 1261/4885ADORA2B 1812/4885ADORA2A 660/4885 |
| US-20220160746-A1 | 3'3'-CYCLIC DINUCLEOTIDE ANALOGUE COMPRISING A CYCLOPENTANYL MODIFIED NUCLEOTIDE AS STING MODULATOR | STING1, MAVS, CGAS | AHCY 1191/4885ADORA2B 1765/4885ADORA2A 652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.